Overview:
Neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO) are significant drivers of vision loss in the United States, and they put substantial burdens on patients – both from the disease itself and the need for regular treatment.
Less-frequent injection protocols using newer anti-VEGF
agents can reduce treatment burden for patients and their caregivers without
compromising efficacy. In this program, expert faculty will review cases that
illustrate the possibilities for providing extended treatment intervals for
patients with neovascular retinal diseases.
Learning Objectives:
Upon completion of this activity, participants will be able to:
- Implement a standardized referral strategy to expedite treatment for nAMD.
- Develop adherence and follow-up workflows for DME after missed visits to support treatment.
- Evaluate clinical stability in RVO to support interval extensions in comanagement.